Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 3 trial of BI 1015550 in idiopathic pulmonary fibrosis
2022-001091-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 1015550 arm with Placebo arm (2 arms). Primary endpoint: Change in FVC at Week 52. Started Jul 2022; status: completed.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-001091-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001091-34.